High-grade glioma in infants and young children is histologically, molecularly, and clinically diverse-Results from the SJYC07 trial and institutional experience.
Jason ChiangAditi BagchiXiaoyu LiSandeep K DhandaJie HuangSoniya N PintoEdgar SiosonJames DaltonRuth G TatevossianSujuan JiaSonia PartapPaul G FisherDaniel C BowersTim HassallCongyu LuAiren Zaldivar-PerazaKaren D WrightAlberto BroniscerIbrahim QaddoumiSanthosh A UpadhyayaAnna VinitskyNoah D SabinBrent A OrrPaul KlimoFrederick A BoopJason M AshfordHeather M ConklinArzu Onar-ThomasXin ZhouDavid W EllisonAmar GajjarGiles W RobinsonPublished in: Neuro-oncology (2023)
HGG in young children is heterogeneous and best defined by integrating histopathological and molecular features. Patients with IHG have relatively good outcomes, yet they endure significant deficits, making them good candidates for therapy de-escalation and trials of molecular targeted therapy.